JP2021098728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021098728A5 JP2021098728A5 JP2021037000A JP2021037000A JP2021098728A5 JP 2021098728 A5 JP2021098728 A5 JP 2021098728A5 JP 2021037000 A JP2021037000 A JP 2021037000A JP 2021037000 A JP2021037000 A JP 2021037000A JP 2021098728 A5 JP2021098728 A5 JP 2021098728A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- orally administered
- acceptable excipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023032872A JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Ｍｃｌ－１阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671306P | 2018-05-14 | 2018-05-14 | |
| US62/671,306 | 2018-05-14 | ||
| US201862749918P | 2018-10-24 | 2018-10-24 | |
| US62/749,918 | 2018-10-24 | ||
| JP2020564228A JP6899975B2 (ja) | 2018-05-14 | 2019-05-13 | Ｍｃｌ−１阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564228A Division JP6899975B2 (ja) | 2018-05-14 | 2019-05-13 | Ｍｃｌ−１阻害剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023032872A Division JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Ｍｃｌ－１阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021098728A JP2021098728A (ja) | 2021-07-01 |
| JP2021098728A5 true JP2021098728A5 (US07981874-20110719-C00313.png) | 2022-10-12 |
| JP7240431B2 JP7240431B2 (ja) | 2023-03-15 |
Family
ID=66770559
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564228A Active JP6899975B2 (ja) | 2018-05-14 | 2019-05-13 | Ｍｃｌ−１阻害剤 |
| JP2021037000A Active JP7240431B2 (ja) | 2018-05-14 | 2021-03-09 | Ｍｃｌ－１阻害剤 |
| JP2023032872A Pending JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Ｍｃｌ－１阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564228A Active JP6899975B2 (ja) | 2018-05-14 | 2019-05-13 | Ｍｃｌ−１阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023032872A Pending JP2023060145A (ja) | 2018-05-14 | 2023-03-03 | Ｍｃｌ－１阻害剤 |
Country Status (29)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3099152C (en) | 2018-05-14 | 2023-10-24 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| JP2022540825A (ja) | 2019-07-09 | 2022-09-20 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状スピロ環誘導体 |
| US11795223B2 (en) | 2019-10-18 | 2023-10-24 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| AU2020374947A1 (en) | 2019-10-31 | 2022-03-31 | Forty Seven, Inc. | Anti-CD47 and anti-CD20 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| JP7441947B2 (ja) | 2019-11-26 | 2024-03-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ１阻害剤を調製するためのプロセス及び中間体 |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| WO2021211922A1 (en) * | 2020-04-16 | 2021-10-21 | Prelude Therapeutics, Incorporated | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
| EP4165050A1 (en) | 2020-06-10 | 2023-04-19 | JANSSEN Pharmaceutica NV | Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| AU2021381769B2 (en) * | 2020-11-19 | 2024-05-30 | Gilead Sciences, Inc. | Processes and intermediates for preparing macrocyclic mcl1 inhibitors |
| EP4263558A1 (en) | 2020-12-17 | 2023-10-25 | JANSSEN Pharmaceutica NV | Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022229102A1 (en) | 2021-04-26 | 2022-11-03 | Janssen Pharmaceutica Nv | Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| EP4351657A1 (en) * | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| WO2022261301A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| IL309378A (en) | 2021-06-23 | 2024-02-01 | Gilead Sciences Inc | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240023628A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CA3237011A1 (en) | 2021-11-16 | 2023-05-25 | Soufyan JERHAOUI | Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1 |
| WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| US20230357274A1 (en) * | 2022-05-04 | 2023-11-09 | Gilead Sciences, Inc. | Salts and polymorphs of certain mcl-1 inhibitors |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| US20090142345A1 (en) | 2005-03-15 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
| KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP3023422A1 (en) | 2007-03-12 | 2016-05-25 | YM BioSciences Australia Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
| SI2182981T1 (sl) | 2007-08-02 | 2013-05-31 | Gilead Biologics, Inc. | Postopki in sestavki za zdravljenje in diagnozo fibroze |
| US8450460B2 (en) | 2008-07-21 | 2013-05-28 | Apogenix Gmbh | Single-chain TNFSF fusion polypeptides |
| WO2010019702A2 (en) | 2008-08-12 | 2010-02-18 | Oncomed Pharmaceuticals, Inc. | Ddr1-binding agents and methods of use thereof |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| CN105622757A (zh) | 2010-02-04 | 2016-06-01 | 吉联亚生物科技有限公司 | 结合赖氨酰氧化酶样2（loxl2）的抗体和其使用方法 |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| PE20131376A1 (es) | 2010-08-27 | 2013-11-25 | Gilead Biologics Inc | Anticuerpos para metaloproteinasa-9 de matriz |
| CN107699585A (zh) | 2010-12-09 | 2018-02-16 | 宾夕法尼亚大学董事会 | 嵌合抗原受体‑修饰的t细胞治疗癌症的用途 |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| JP6101205B2 (ja) | 2011-08-23 | 2017-03-22 | 中外製薬株式会社 | 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体 |
| GB201115529D0 (en) | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
| WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
| WO2014047624A1 (en) | 2012-09-24 | 2014-03-27 | Gilead Sciences, Inc. | Anti-ddr1 antibodies |
| CA2895782C (en) | 2012-12-21 | 2017-08-22 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
| NZ708870A (en) | 2012-12-21 | 2016-09-30 | Gilead Calistoga Llc | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| JP6030783B2 (ja) | 2013-06-14 | 2016-11-24 | ギリアード サイエンシーズ， インコーポレイテッド | ホスファチジルイノシトール３−キナーゼ阻害剤 |
| US9657023B2 (en) | 2013-07-30 | 2017-05-23 | Gilead Connecticut, Inc. | Polymorph of Syk inhibitors |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
| AU2015235944B2 (en) * | 2014-03-27 | 2020-06-25 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| JP6765968B2 (ja) | 2014-04-10 | 2020-10-07 | シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート | 薬物制御による導入遺伝子の発現 |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| AU2015320675B2 (en) | 2014-09-26 | 2018-10-18 | Gilead Sciences, Inc. | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds |
| MX2017007138A (es) | 2014-12-03 | 2017-08-28 | Juno Therapeutics Inc | Metodos y composiciones para terapia celular adoptiva. |
| JP6821568B2 (ja) | 2014-12-15 | 2021-01-27 | ベリカム ファーマシューティカルズ， インコーポレイテッド | 治療用細胞のコントロールされた排除方法 |
| NZ736709A (en) | 2015-05-15 | 2019-05-31 | Gilead Sciences Inc | Benzimidazole and imidazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase |
| EP3303586A1 (en) | 2015-05-29 | 2018-04-11 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
| SG10202110257UA (en) | 2015-09-17 | 2021-10-28 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| WO2017147410A1 (en) * | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| WO2019036575A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | MCL-1 PROTEIN INHIBITING COMPOUNDS |
| WO2019046150A1 (en) | 2017-08-29 | 2019-03-07 | Amgen Inc. | MACROCYCLIC COMPOUNDS FOR INHIBITING MCL-1 PROTEIN |
| CN111417394B (zh) | 2017-10-19 | 2023-11-07 | 帝人制药株式会社 | 苯并咪唑衍生物及其用途 |
| EP3762393B1 (en) | 2018-03-05 | 2023-01-11 | Amgen Inc. | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists |
| IL278698B2 (en) | 2018-05-14 | 2024-06-01 | Reata Pharmaceuticals Inc | Bi-aryl amides with sugar groups that are adapted to the treatment of diseases related to the heat stroke protein pathway |
| CA3099152C (en) | 2018-05-14 | 2023-10-24 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| EA202092586A1 (ru) | 2018-05-15 | 2021-03-10 | Лундбекк Ла-Хойя Рисерч Сентер, Инк. | Ингибиторы magl |
| BR112021001263A2 (pt) | 2018-07-24 | 2021-04-27 | Epizyme, Inc. | compostos, seus usos, método para tratar câncer e método para modular uma atividade de smarca2 |
| BR112021008796A2 (pt) | 2018-11-09 | 2021-08-03 | Prelude Therapeutics, Incorporated | derivados de espiro-sulfonamida como inibidores de proteína de leucemia-1 de células mieloides (mcl-1) |
| CN112867722B (zh) | 2019-01-18 | 2022-09-23 | 苏州亚盛药业有限公司 | 作为mcl-1抑制剂的大螺环醚(macrocyclic spiroethers) |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| JP7441947B2 (ja) | 2019-11-26 | 2024-03-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ１阻害剤を調製するためのプロセス及び中間体 |
| JP2021161114A (ja) | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Ｍｃｌ−１化合物のメチル化 |
| BR112022022400A2 (pt) | 2020-05-06 | 2022-12-13 | Amgen Inc | Síntese de intermediários de álcool vinílico protegidos |
| TWI827924B (zh) | 2020-05-06 | 2024-01-01 | 美商安進公司 | 大環Mcl-1抑制劑中間體的閉環合成 |
| EP4165050A1 (en) | 2020-06-10 | 2023-04-19 | JANSSEN Pharmaceutica NV | Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| MX2023000438A (es) | 2020-07-08 | 2023-02-09 | Janssen Pharmaceutica Nv | Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1. |
| AU2021381769B2 (en) | 2020-11-19 | 2024-05-30 | Gilead Sciences, Inc. | Processes and intermediates for preparing macrocyclic mcl1 inhibitors |
-
2019
- 2019-05-13 CA CA3099152A patent/CA3099152C/en active Active
- 2019-05-13 HR HRP20220215TT patent/HRP20220215T1/hr unknown
- 2019-05-13 KR KR1020237022152A patent/KR102666717B1/ko active IP Right Grant
- 2019-05-13 ES ES19728793T patent/ES2907923T3/es active Active
- 2019-05-13 MX MX2020012137A patent/MX2020012137A/es unknown
- 2019-05-13 WO PCT/US2019/032053 patent/WO2019222112A1/en unknown
- 2019-05-13 KR KR1020247015778A patent/KR20240074001A/ko active Search and Examination
- 2019-05-13 CN CN202310897123.9A patent/CN117304130A/zh active Pending
- 2019-05-13 UA UAA202006695A patent/UA125163C2/uk unknown
- 2019-05-13 KR KR1020207035485A patent/KR102551319B1/ko active IP Right Grant
- 2019-05-13 AU AU2019269391A patent/AU2019269391B2/en active Active
- 2019-05-13 SG SG11202010964VA patent/SG11202010964VA/en unknown
- 2019-05-13 US US16/410,457 patent/US10703733B2/en active Active
- 2019-05-13 DK DK19728793.1T patent/DK3793565T3/da active
- 2019-05-13 PE PE2020001829A patent/PE20210004A1/es unknown
- 2019-05-13 PT PT197287931T patent/PT3793565T/pt unknown
- 2019-05-13 PL PL19728793T patent/PL3793565T3/pl unknown
- 2019-05-13 LT LTEPPCT/US2019/032053T patent/LT3793565T/lt unknown
- 2019-05-13 HU HUE19728793A patent/HUE057852T2/hu unknown
- 2019-05-13 IL IL291430A patent/IL291430B2/en unknown
- 2019-05-13 EP EP19728793.1A patent/EP3793565B1/en active Active
- 2019-05-13 SI SI201930181T patent/SI3793565T1/sl unknown
- 2019-05-13 EP EP21218221.6A patent/EP4029868A1/en active Pending
- 2019-05-13 CN CN201980032695.2A patent/CN112118845B/zh active Active
- 2019-05-13 CR CR20200544A patent/CR20200544A/es unknown
- 2019-05-13 JP JP2020564228A patent/JP6899975B2/ja active Active
- 2019-05-13 BR BR112020021648-8A patent/BR112020021648A2/pt unknown
- 2019-05-14 TW TW108116508A patent/TWI719478B/zh active
- 2019-05-14 TW TW110107128A patent/TWI813957B/zh active
-
2020
- 2020-04-23 US US16/857,021 patent/US10988451B2/en active Active
- 2020-10-27 IL IL278336A patent/IL278336B/en unknown
- 2020-11-03 PH PH12020551881A patent/PH12020551881A1/en unknown
- 2020-11-10 CL CL2020002919A patent/CL2020002919A1/es unknown
- 2020-11-10 ZA ZA2020/07007A patent/ZA202007007B/en unknown
- 2020-11-10 CO CONC2020/0014009A patent/CO2020014009A2/es unknown
-
2021
- 2021-02-09 US US17/171,201 patent/US11643400B2/en active Active
- 2021-03-09 JP JP2021037000A patent/JP7240431B2/ja active Active
- 2021-05-25 AU AU2021203373A patent/AU2021203373B2/en active Active
-
2022
- 2022-03-16 CY CY20221100208T patent/CY1125065T1/el unknown
-
2023
- 2023-03-03 JP JP2023032872A patent/JP2023060145A/ja active Pending
- 2023-03-09 US US18/181,336 patent/US20230312490A1/en active Pending
- 2023-11-24 AU AU2023270332A patent/AU2023270332A1/en active Pending
